Lakewood-Amedex Biotherapeutics (LABT) Stock Price, News & Analysis
Why is LABT Stock Down Today?
What Changed
Price Move History
- Daily moves over 5%
- 53 102 sessions, April 23, 2026 to September 17, 2026
- Largest daily move
- +83.3% close of July 22, 2026
Company Description
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing antimicrobial drug candidates for infectious diseases. The company’s research is centered on the Bisphosphocin® class, a novel class of fast-acting, broad-spectrum antimicrobials discovered by Lakewood-Amedex and intended to address bacterial infections, including strains associated with antimicrobial resistance such as MRSA and VRE. Its common stock trades on the Nasdaq Capital Market under the symbol LABT following an April 2026 direct listing.
Antimicrobial platform and lead compound
The company’s lead compound, Nu-3, is being developed as a topically delivered antimicrobial treatment for infected diabetic foot ulcers. Lakewood-Amedex describes Nu-3 as part of its Bisphosphocin platform. Reported in vitro data for the class indicate rapid bacterial killing through pH- and concentration-dependent destabilization of bacterial cell membranes. The platform is also being explored in preclinical studies for potential use in complicated urinary tract infection and pulmonary infections.
Lakewood-Amedex’s operating model is based on advancing proprietary antimicrobial compounds through research, preclinical work, clinical development, and regulatory preparation. As a clinical-stage biotechnology issuer, the company’s durable business profile is defined by its drug-development pipeline rather than commercial product sales.
Public company status
Lakewood-Amedex Biotherapeutics is incorporated in Nevada and maintains principal executive offices in University Park, Florida. Its SEC registration materials identify the company within pharmaceutical preparations. Public-company disclosures for LABT cover securities registration, corporate governance, board composition, capital structure, business risks, and updates related to its antimicrobial development programs.
Stock Performance
Lakewood-Amedex Biotherapeutics (LABT) closed at $1.86 on September 17, 2026. Over the past month, the price has lost 13.9%.
LABT Metrics & Rankings
Price returns through September 17, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Lakewood-Amedex Biotherapeutics has 10 recent news articles, with the latest published today. Of the recent coverage, 3 articles coincided with positive price movement and 6 with negative movement. Key topics include clinical trial. View all LABT news →
SEC Filings
Lakewood-Amedex Biotherapeutics has filed 10 recent SEC filings, including 3 Form 424B3, 3 Form SCHEDULE 13G, 1 Form 10-Q, 1 Form DEF 14A. The most recent filing was submitted on August 17, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LABT SEC filings →
Financial Highlights
Upcoming Events
Phase 2a start
Lakewood-Amedex Biotherapeutics has 1 upcoming scheduled event. Investors can track these dates to stay informed about potential catalysts that may affect the LABT stock price.
Short Interest History
Short interest in Lakewood-Amedex Biotherapeutics (LABT) currently stands at 61.4 thousand shares, up 9.2% from the previous reporting period, representing 4.1% of the float. Since April 2026, short interest has decreased by 18.9%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Lakewood-Amedex Biotherapeutics (LABT) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
LABT Company Profile & Sector Positioning
Lakewood-Amedex Biotherapeutics (LABT) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Lakewood-Amedex Biotherapeutics (LABT) received central and site IRB approvals and confirmed clinical site readiness to begin a Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers. The study will evaluate the safety and efficacy of Nu-3, the company’s lead product candidate, in patients with iDFU, a condition described as a leading cause of lower-limb amputations worldwide. The trial is designed to build on positive preclinical safety data and early exploratory findings in which Nu-3 was well-tolerated and showed trends of improved antimicrobial response and wound healing. Nu-3 is a proprietary topical gel that uses a mechanism of action aimed at destabilizing microbial cell membranes, which is described as providing a high barrier to the development of antimicrobial resistance. The company states that this development remains aligned with federal mandates from the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria for innovative, resistance-evading therapies.